These studies will help establish whether changes in MCP‐1 correlate with symptom exacerbations or reflect the underlying inflammatory state, and whether MCP‐1 could serve as a biomarker for disease progression or treatment response in TS. Here, CCL2 is linked to Timothy syndrome.